Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

373 results about "Immune rejection" patented technology

Immune rejection is a complication that may occur with stem cell transplantation. When it occurs the immune system of a person sees the transplanted cells as 'foreign' and thus begins a fast and possibly aggressive response to attack those cells that are not recognized as 'self.' During a chronic rejection response, the attack is:

Preparation method of allogenic mesenchymal stem cells by CRISPR (clustered regularly interspaced short palindromic repeats) technique editing and IGF (insulin-like growth factor) optimization and application of allogenic mesenchymal stem cells in treating myocardial infarction

ActiveCN105985985AImprove anti-apoptotic abilityPromote homingUnknown materialsFermentationAntigenInflammatory factors
The invention belongs to the field of allogenic mesenchymal stem cells, and particularly relates to a preparation method of allogenic mesenchymal stem cells by CRISPR (clustered regularly interspaced short palindromic repeats) technique editing and IGF (insulin-like growth factor) optimization and application of the allogenic mesenchymal stem cells in treating myocardial infarction. The preparation method comprises the following steps: carrying out separation by density gradient centrifugation to obtain allogenic single karyocytes, and carrying out adherent culture to obtain mesenchymal stem cells; designing a mesenchymal stem cell surface antigen B2M-gRNA and an inflammatory factor TNF-alpha-gRNA; establishing recombinant slow virus particles, and transfecting the mesenchymal stem cells; optimizing the mesenchymal stem cells by using IGF-1; and preparing drugs for treating myocardial infarctions by using the modified and optimized mesenchymal stem cells. The CRISPR/Cas9 technique is utilized to remove the antigens capable of causing immunological rejection and the inflammatory factors capable of causing inflammatory reaction on the mesenchymal stem cell surface, and the IGF-1 is utilized to enhance the apoptosis resistance of the mesenchymal stem cells and promote the homing of the mesenchymal stem cells, thereby providing a new technical scheme for preparing drugs for treating cardiovascular diseases in clinic. The prepared allogenic mesenchymal stem cells can not cause immunological rejection after cell transplantation.
Owner:SUZHOU UNIV

Sub totipotential stem cell and preparation method and application thereof

The invention discloses a method for preparing a population of?human pluripotent stem cells and the application thereof. The preparation of stem cells is characterized by comprising the following steps: CD151<+>, CD31<->, Sox<2+> pluripotent stem cells are separated and collected from human umbilical cord and or placenta tissues; the cells adhere to grow in a culture vessel under a predetermined condition and expand through passage 20 or above to be still stable in gene expression. The population of cells of this invention do not form teratoma after injection into animals. The human pluripotent stem cells highly express CD151, OCT4 and Sox-2 as specific markers of embryonic stem cells, as well as specific markers of epidermic cells, endothelial cells, thrombocytes, dendritic cells, while lack expression of CD31, CD34, CD45 and HLA-II. The pluripotent stem cells are also characterized as being able to adhere to tissue culture plastic and having the potential to differentiate into three germ layers: endoderm, mesoderm and ectoderm. These pluripotent stem cells are able to be used as carrier cells of gene therapy and for the treatment of diseases caused by cell damage or cell aging. The present invention provides a method of isolating, purifying and culturally expanding of a population of human pluripotent stem cell for preparing the high purity injection preparation. The preparation of stem cells has a good therapeutic effect on the treatment of diseases caused by cell damage or cell aging in animal and human clinical trials. The preparation also has no toxic side effect and no immune rejection.
Owner:BEIJING HEALTH & BIOTECH (H&B) CO LTD

Construction method of tissue engineering blood vessel

The invention relates to a construction method of a tissue engineering blood vessel which belongs to the tissue engineering field. The construction method of the tissue engineering blood vessel includes the following steps: (1) tubular autologous living tissue bed frame material is connected to a continuous perfusion bioreactor under the vitro aseptic condition, and the outside of a vessel lumen is filled with culture medium; (2) endothelial cells obtained from the vitro culture medium is suspended at M199 or vascular endothelium-like cells generating from the induction of bone marrow mono nucleus cells are suspended at endothelial progenitor cell culture medium and are inoculated on the inner surface of the vessel lumen according to a high density planting method; (3) after the endothelial cells or the vascular endothelium-like cells are adhered, the inner cycle and the external cycle of the vessel lumen are communicated and the blood circulation is simulated to provide proper pressure stimulation and shear stress stimulation and the endothelial cells or the vascular endothelium-like cells are cultured for 5-7 days in a carbon dioxide incubator. The construction method has the advantages that perfect cell compatibility and enough mechanical strength are provided, the defects of immunological rejection and inflammation reaction, etc. caused by heterogenetic material are overcome, and the preparation time is short.
Owner:XUANWU HOSPITAL OF CAPITAL UNIV OF MEDICAL SCI

Tissue mending material with biological activity and preparation method thereof

The invention relates to a tissue repairing material with bioactivity and a preparation method thereof. The material is made by compounding human body living cells, and extracellular matrixes and cell growth factors synthesized and excreted by the human body living cells on the acellular small intestine submucosa. Natural antigen components are removed from the prepared tissue repairing material with bioactivity, and when the tissue repairing material is applied to a wound, the tissue repairing material can survive and directly take part in the repair of the wound to continuously synthesize and excrete growth factors, guide the cells around the wound to grow in and the creation of blood vessel, and induce the differentiation of stem cells to skin cells, thereby obviously promoting the wound healing; besides, the tissue repairing material not only has part of the characteristics of human body tissues and the good mechanical property of the acellular small intestine submucosa, but also has high biocompatibility to human body, obviously reduces the immune rejection; at the same time, the prepared tissue repairing material can cover the surface of wound, fill the defection of soft tissues, promote the growth and proliferation of the cells around the wound, repair the defection of the soft tissue organs, and promote the wound healing.
Owner:SHAANXI RUISHENG BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products